We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.05B
AUM Growth
+$146M
Cap. Flow
-$430M
Cap. Flow %
-8.52%
Top 10 Hldgs %
43.4%
Holding
134
New
26
Increased
24
Reduced
35
Closed
22

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$129M
2
MRK icon
Merck
MRK
+$76.6M
3
GH icon
Guardant Health
GH
+$43.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$31.5M
5
QURE icon
uniQure
QURE
+$28.3M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$87M
2
LLY icon
Eli Lilly
LLY
+$65.3M
3
APLS
Apellis Pharmaceuticals
APLS
+$61M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.8M
5
CI icon
Cigna
CI
+$56.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Miscellaneous 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
76
Regeneron Pharmaceuticals
REGN
$81.7B
$11.4M 0.23%
+14,700
New +$11.3M
CARL
77
Carlsmed
CARL
$461M
$11.3M 0.22%
1,252,600
– –
BIIB icon
78
Biogen
BIIB
$32.3B
$11.3M 0.22%
+61,600
New +$11.4M
QGEN icon
79
CALL
Qiagen
QGEN
$8.9B
$10M 0.2%
+250,000
New +$11.8M
KNSA icon
80
Kiniksa Pharmaceuticals
KNSA
$6.1B
$8.7M 0.17%
180,599
-6,600
-4% -$292K
KROS icon
81
Keros Therapeutics
KROS
$219M
$8.38M 0.17%
759,155
-45,057
-6% -$696K
GILD icon
82
Gilead Sciences
GILD
$181B
$8.31M 0.16%
+59,600
New +$8.35M
HRTX icon
83
Heron Therapeutics
HRTX
$61.4M
$7.85M 0.16%
+9,816,940
New +$11.4M
AVTX icon
84
Avalo Therapeutics
AVTX
$1.05B
$7.09M 0.14%
475,165
-712,135
-60% -$11.1M
TECX
85
Tectonic Therapeutic
TECX
$695M
$7M 0.14%
226,600
-348,000
-61% -$8.56M
ACET icon
86
Adicet Bio
ACET
$84.9M
$7M 0.14%
1,027,944
– –
CMPS
87
Compass Pathways
CMPS
$1.9B
$6.36M 0.13%
+1,150,646
New +$7.74M
PVLA
88
CALL
Palvella Therapeutics
PVLA
$2.16B
$6.23M 0.12%
+50,000
New +$5.22M
PHVS icon
89
Pharvaris
PHVS
$2.48B
$5.8M 0.12%
205,400
– –
ALXO icon
90
ALX Oncology
ALXO
$277M
$5.75M 0.11%
+2,866,256
New +$5.46M
AORT icon
91
Artivion
AORT
$1.3B
$5.53M 0.11%
+151,000
New +$5.96M
NSPR icon
92
InspireMD
NSPR
$39.5M
$5.11M 0.1%
3,133,405
– –
RVMD icon
93
Revolution Medicines
RVMD
$44.5B
$5.06M 0.1%
52,000
+26,100
+101% +$2.64M
ADCT icon
94
ADC Therapeutics
ADCT
$147M
$4.94M 0.1%
1,318,026
-4,504,828
-77% -$17.8M
PTGX icon
95
Protagonist Therapeutics
PTGX
$9.34B
$4.44M 0.09%
42,100
+20,400
+94% +$1.81M
PALI icon
96
Palisade Bio
PALI
$350M
$4.08M 0.08%
2,333,000
+461,580
+25% +$839K
ANRO icon
97
Alto Neuroscience
ANRO
$1.38B
$3.77M 0.07%
167,500
+42,500
+34% +$788K
SVRA icon
98
Savara
SVRA
$1.08B
$3.47M 0.07%
+635,000
New +$3.53M
CGEM icon
99
Cullinan Oncology
CGEM
$1.4B
$3.45M 0.07%
243,006
-27,000
-10% -$347K
SLNO
100
CALL
DELISTED
Soleno Therapeutics
SLNO
$3.35M 0.07%
+100,000
New +$3.92M
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2026 Portfolio in Review

As of Q1 2026, OrbiMed held 134 positions worth $5.05B, up 3% from $4.9B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

OrbiMed withdrew a net $430M in Q1 2026, closing 22 positions and reducing 35 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in AstraZeneca worth $132M.

  • OrbiMed's largest Q1 2026 buy was AstraZeneca: 670,200 shares worth $132M.
  • OrbiMed added most to Mineralys Therapeutics in Q1 2026, an estimated $31.5M increase.
  • OrbiMed's biggest Q1 2026 reduction was Eli Lilly, cutting an estimated $65.3M.
  • OrbiMed fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 43% of its $5.05B portfolio in Q1 2026.
  • OrbiMed opened 26 new positions and closed 22 in Q1 2026.
  • OrbiMed's portfolio value rose 3% quarter-over-quarter to $5.05B.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.